Drug Trial Radar · NCT05959694
A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .
Last checked: Nov 19, 2026Latest source record: Oct 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
107
Planned (sponsor's estimate)
Start
Oct 11, 2023
Primary completion
Dec 2025
Study completion Jun 2026
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase Ib/II clinical trial to evaluate the safety and efficacy of TQB3909 tablets in patients with recurrent or refractory CLL/SLL.
Conditions
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
Interventions
TQB3909 tabletDrug
TQB3909 is an inhibitor targeting at B-cell lymphoma (BCL)-2 protein.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AE)Time frame: Up to 34 months.
- Severity of adverse events (AE)Time frame: Up to 34 months.
- Incidence of serious adverse events (SAE)Time frame: Up to 34 months.
- Severity of serious adverse events (SAE)Time frame: Up to 34 months.
- Incidence of abnormal laboratory examination indexes.Time frame: Up to 34 months.
- Severity of abnormal laboratory examination indexes.Time frame: Up to 34 months.
- Recommended phase II dose (RP2D)Time frame: Up to 18 months
- Objective remission rate (ORR) determined by Independent Review Committee (IRC)Time frame: Up to 34 months
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
Anqing Municipal Hospital
Anqing, Anhui, China · Recruiting
Gansu province Wuwei tumour hospital
Wuwei, Gansu, China · Recruiting
Sun Yat-Sen University Cancer Canter
Guangzhou, Guangdong, China · Recruiting
Affiliated Hospital of Chengde Medical College
Chengde, Hebei, China · Recruiting
Harbin first hospital
Harbin, Heilongjiang, China · Recruiting
The Second Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
Jiangsu Provincial People's Hospital
Nanjing, Jiangsu, China · Recruiting
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China · Recruiting
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China · Recruiting
Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China · Recruiting
Jiangxi Cancer Hospital
Nanchang, Jiangxi, China · Recruiting
Shengjing Hospital Affiliated to China Medical University
Shenyang, Liaoning, China · Recruiting
Qilu Hospital of Shandong University
Jinan, Shandong, China · Recruiting
Linyi people's hospital
Linyi, Shandong, China · Recruiting
Tai 'an Central Hospital
Tai’an, Shandong, China · Recruiting
Shanghai Tongren Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Peace Hospital Affiliated to Changzhi Medical College
Changzhi, Shanxi, China · Recruiting
Affiliated hospital of southwest medical university
Luzhou, Sichuan, China · Recruiting
Mianyang Central Hospital
Mianyang, Sichuan, China · Recruiting
Yibin Second People's Hospital
Yibin, Sichuan, China · Recruiting
Tianjin Cancer Hospital
Tianjin, Tianjin Municipality, China · Recruiting
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang Uygur Autonomous Region, China · Recruiting
The First Affiliated Hospital of Ningbo University
Ningbo, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.